Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 2306-2312, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hoermann, R.
Right arrow Articles by Mann, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoermann, R.
Right arrow Articles by Mann, K.

Clinical Chemistry, Vol 40, 2306-2312, Copyright © 1994 by American Association for Clinical Chemistry

Immunological recognition and clinical significance of nicked human chorionic gonadotropin in testicular cancer

R Hoermann, P Berger, G Spoettl, F Gillesberger, A Kardana, LA Cole and K Mann
Department of Endocrinology, University of Essen, Germany.

We studied the physical properties, immunological recognition, and clinical significance of nicked human chorionic gonadotropin (hCGn) in testicular cancer. Upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions, the beta-subunit of hCGn (hCG beta n) dissociated into two peptides, and, by reversed-phase chromatography, hCG beta n was found to be less hydrophobic than hCG beta. Immunologically, hCGn lacked two epitopes specific for holo-hCG (c1, c2), whereas at least five hCG beta epitopes (beta 1-beta 5) were preserved, and, as a result, recognition of hCGn by different hCG assays varied widely. In 309 sera and 88 urine samples from patients with seminomatous or nonseminomatous testicular cancer, hCG-only, hCG+hCGn, and hCG+hCGn+hCG beta+hCG beta n+hCG beta core-fragment assays gave parallel results. hCGn was more abundant in urine than in serum samples. In conclusion, hCGn lacks two conformationally dependent epitopes of hCG, causing a change in hydrophobicity and explaining its failure to react in certain holo-hCG assays. Recognition of hCGn, however, does not seem to be crucial in the routine use of serum hCG as a tumor marker in patients with testicular cancer.


The following articles in journals at HighWire Press have cited this article:


Home page
 Hum Reprod UpdateHome page
S.F. de Medeiros and R.J. Norman
Human choriogonadotrophin protein core and sugar branches heterogeneity: basic and clinical insights
Hum. Reprod. Update, January 1, 2009; 15(1): 69 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
U.-H. Stenman, A. Tiitinen, H. Alfthan, and L. Valmu
The classification, functions and clinical use of different isoforms of HCG
Hum. Reprod. Update, November 1, 2006; 12(6): 769 - 784.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. Singh and W. E. Merz
Disulfide Bond Formation Is Not Required for Human Chorionic Gonadotropin Subunit Association. STUDIES WITH DITHIOTHREITOL IN JEG-3 CELLS
J. Biol. Chem., April 14, 2000; 275(16): 11765 - 11770.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Kovalevskaya, S. Birken, T. Kakuma, J. Schlatterer, and J. F. O'Connor
Evaluation of Nicked Human Chorionic Gonadotropin Content in Clinical Specimens by a Specific Immunometric Assay
Clin. Chem., January 1, 1999; 45(1): 68 - 77.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.